Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$6.50 +3.8%	$5.13	$1.62 ▼ $7.27	$558.02M	-0.59	1.19 million shs	1.17 million shs
MOLN Molecular Partners	$3.66 -0.7%	$3.88	$3.36 ▼ $12.22	$149.01M	1.11	14,969 shs	5,613 shs
MRVI Maravai LifeSciences	$2.38 +4.8%	$2.13	$1.67 ▼ $10.03	$578.08M	0.25	2.33 million shs	2.26 million shs
SAGE Sage Therapeutics	$9.28 +0.3%	$7.35	$4.62 ▼ $13.47	$579.24M	0.18	1.28 million shs	930,050 shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	+3.83%	+27.45%	+37.71%	+77.60%	+255.19%
MOLN Molecular Partners	-0.70%	-2.29%	-8.38%	-14.21%	-49.95%
MRVI Maravai LifeSciences	+4.85%	+18.41%	+6.73%	+0.85%	-65.71%
SAGE Sage Therapeutics	+0.32%	+1.64%	+42.33%	+12.08%	-14.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	3.7345 of 5 stars	4.5	3.0	0.0	2.0	3.3	0.6
MOLN Molecular Partners	2.8794 of 5 stars	3.8	5.0	0.0	2.0	0.0	0.6
MRVI Maravai LifeSciences	3.7502 of 5 stars	3.1	3.0	4.4	1.5	0.8	0.6
SAGE Sage Therapeutics	2.8448 of 5 stars	2.0	1.0	4.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	2.92	Moderate Buy	$11.00	69.23% Upside
MOLN Molecular Partners	3.50	Strong Buy	$12.00	227.51% Upside
MRVI Maravai LifeSciences	2.25	Hold	$6.64	178.94% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.74% Downside

Current Analyst Ratings Breakdown

Latest MOLN, SAGE, AMLX, and MRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/24/2025	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$17.00
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	AMLX Amylyx Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	6.63	N/A	N/A	$2.40 per share	2.71
MOLN Molecular Partners	$5.65M	26.19	N/A	N/A	$3.99 per share	0.92
MRVI Maravai LifeSciences	$259.18M	2.34	$0.65 per share	3.67	$2.28 per share	1.04
SAGE Sage Therapeutics	$41.24M	14.09	N/A	N/A	$7.60 per share	1.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-77.21%	-63.84%	8/6/2025 (Estimated)
MOLN Molecular Partners	-$61.39M	-$1.92	N/A	N/A	N/A	-1,043.01%	-42.20%	-38.12%	8/25/2025 (Estimated)
MRVI Maravai LifeSciences	-$144.85M	-$1.14	N/A	N/A	N/A	-67.14%	-12.91%	-6.87%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest MOLN, SAGE, AMLX, and MRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	MOLN Molecular Partners	-$0.3855	-$0.50	-$0.1145	-$0.50	N/A	N/A
5/12/2025	Q1 2025	MRVI Maravai LifeSciences	-$0.07	-$0.08	-$0.01	-$0.21	$44.01 million	$46.85 million
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MOLN Molecular Partners	N/A	N/A	N/A	N/A	N/A
MRVI Maravai LifeSciences	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
MOLN Molecular Partners	N/A	15.28	15.28
MRVI Maravai LifeSciences	0.60	5.96	5.17
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
MOLN Molecular Partners	26.55%
MRVI Maravai LifeSciences	50.25%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
MOLN Molecular Partners	5.93%
MRVI Maravai LifeSciences	2.11%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
MOLN Molecular Partners	180	40.38 million	37.98 million	Not Optionable
MRVI Maravai LifeSciences	610	254.66 million	249.29 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

MOLN, SAGE, AMLX, and MRVI Headlines

Recent News About These Companies

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23, 2025 | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22, 2025 | msn.com

Robert W. Baird Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 21, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20, 2025 | marketbeat.com

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

June 20, 2025 | mmm-online.comM

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19, 2025 | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19, 2025 | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18, 2025 | biospace.comB

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18, 2025 | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17, 2025 | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17, 2025 | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.comA

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17, 2025 | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 16, 2025 | pharmaphorum.comP

Supernus makes depression drug play with $795m Sage buyout

June 16, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MOLN, SAGE, AMLX, and MRVI Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$6.50 +0.24 (+3.83%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$6.43 -0.07 (-1.14%)

As of 04:20 AM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Molecular Partners NASDAQ:MOLN

$3.66 -0.03 (-0.70%)

Closing price 06/26/2025 03:06 PM Eastern

Extended Trading

$3.68 +0.02 (+0.44%)

As of 04:10 AM Eastern

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Maravai LifeSciences NASDAQ:MRVI

$2.38 +0.11 (+4.85%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.39 +0.01 (+0.42%)

As of 06/26/2025 04:54 PM Eastern

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Sage Therapeutics NASDAQ:SAGE

$9.28 +0.03 (+0.32%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$9.24 -0.04 (-0.42%)

As of 06/26/2025 04:08 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time